Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label intra-articular AMB-05X for tenosynovial giant cell tumor of the knee
NL-OMON50981Phase 2Active, not recruiting
- Sponsor
- AmMax Bio
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ABM-05X, sponsored by AmMax Bio. Started May 2021; status: active, not recruiting.
02
Drugs
ABM-05X
Beyond the preview
Go deeper on NL-OMON50981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50981.